We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00089492
Recruitment Status : Completed
First Posted : August 6, 2004
Last Update Posted : November 2, 2016
Information provided by (Responsible Party):
Hoffmann-La Roche